Leveraging the Revolutionary Science of Checkpoint Inhibitors to Create Turbocharged Vaccines for Animal and Human Health

MBF Therapeutics is a life science company focused on the development of gene-based, immunotherapeutic vaccines for use in veterinary medicine and human health. Using proprietary vaccine platform & delivery system technology, MBF Therapeutics’ checkpoint inhibitor therapies have the potential of transforming the treatment of cancer and prevention of infectious diseases.

THE LATEST IN THE

NEWS:

Partnership Opportunities with MBF Therapeutics

In addition to developing effective therapeutic and prophylactic vaccines for unmet needs in animal health, the MBF Therapeutics team is dedicated to delivering long-term value to our investors by leveraging key partnerships with various research institutions, clinical testing facilities and a USDA licensed manufacturer.

MBF Therapeutics—The First Company to Develop an Animal Health Vaccine Using Gene-based Checkpoint Inhibitors

MBF Therapeutics’ lead product is an immunotherapeutic vaccine for canine melanoma. Two pilot studies have been completed and the vaccine:

​

• Was shown to be safe

• Elicited a robust immune response in 100% of dogs treated

• Has potential for a conditional registration as early as 2020.

​

MBF Therapeutics also has a strong pipeline of products, including vaccines for other cancers in companion animals, as well as economically significant infectious swine diseases.